ERBB2 and endometrial cancer: Indeed, a wide variety of HER2-targeted radiotherapeutics—including those labeled with β-emitting (i.e., 131I and 177Lu) and α-emitting (e.g., 225Ac, 212Pb, 211At) nuclides—have been explored preclinically and clinically, yet none have been explored in the context of endometrial cancer (31,32).